A new approach to treating muscle-invasive bladder cancer—combining immunotherapy with chemotherapy and radiation—is showing promise in sparing patients from radical cystectomy, the complete removal of the bladder. Early results from a Phase 2 clinical trial, dubbed INDIBLADE, suggest that a regimen of ipilimumab and nivolumab, followed by chemoradiotherapy, can significantly reduce the require for surgery in a substantial portion of patients. This offers a potentially less debilitating path forward for those diagnosed with this aggressive form of cancer.
Muscle-invasive bladder cancer, where the cancer has grown into the muscle layer of the bladder wall, is a serious diagnosis. Traditionally, the standard of care has been radical cystectomy, a major surgery that can have significant side effects and impact quality of life. The goal of the INDIBLADE trial is to determine if a combination of immunotherapy and chemoradiotherapy can effectively control the cancer, allowing patients to avoid or delay this invasive procedure. The trial is focused on identifying patients who may benefit most from this bladder-sparing strategy.
The immunotherapy component of the treatment involves two drugs, ipilimumab and nivolumab, both manufactured by Bristol Myers Squibb. These drugs are checkpoint inhibitors, meaning they work by blocking proteins that prevent the immune system from attacking cancer cells, essentially unleashing the body’s own defenses against the disease. Following the immunotherapy phase, patients receive chemoradiotherapy, a combination of chemotherapy drugs and radiation therapy, to further target and destroy any remaining cancer cells. The trial is being funded by Bristol Myers Squibb, as noted in disclosures related to competing interests.
Several researchers involved in the study have disclosed financial ties to pharmaceutical companies. For example, M.S. Van der Heijden has received institutional funding from Bristol Myers Squibb to finance the INDIBLADE trial. C.H., S.K.C., S.S., and A.C.E. Are all full-time employees of Natera, Inc., and hold stocks or options to own stocks in the company. Natera’s Signatera ctDNA assay is being investigated in other cancer trials, including a Phase 2 study in non-minor cell lung cancer, as reported in September 2018. Other researchers have received consulting fees or research support from companies including Johnson & Johnson, Merck, AstraZeneca, and Bayer. No medical writers were involved in drafting the manuscript.
Understanding the Role of ctDNA in Cancer Treatment
Natera, Inc., a company whose employees are involved in the INDIBLADE trial, specializes in cell-free DNA (cfDNA) testing. Their Signatera assay, a custom circulating tumor DNA (ctDNA) test, is being used in other research to identify minimal residual disease (MRD) after surgery, potentially guiding decisions about further treatment. As reported by BioSpace, Natera has a prior collaboration with Dr. Charles Swanton and the UCL Cancer Institute team, which contributed to the development of their approach in non-small cell lung cancer.
Competing Interests and Transparency
The disclosures highlight the importance of transparency in medical research. While financial relationships between researchers and pharmaceutical companies are common, they are carefully scrutinized to ensure objectivity and prevent bias. The detailed reporting of these interests, as outlined in the study’s disclosures, is a standard practice aimed at maintaining the integrity of the research process. Researchers also disclosed relationships with companies like Cepheid, Astellas, Siemens, Janssen, Novartis, and Pfizer.
The INDIBLADE Trial Design
The INDIBLADE trial is designed to assess the efficacy and safety of the ipilimumab and nivolumab combination followed by chemoradiotherapy in patients with muscle-invasive bladder cancer. Researchers are evaluating whether this approach can achieve a complete pathological response, meaning no cancer cells are found in the bladder after treatment. The trial’s primary endpoint is the rate of patients who avoid cystectomy. The study is ongoing, and further results are needed to confirm these initial findings.
The potential benefits of a bladder-sparing approach are significant. Radical cystectomy can lead to complications such as urinary incontinence, sexual dysfunction, and a reduced quality of life. If the INDIBLADE trial demonstrates that this combination therapy can effectively control the cancer while preserving bladder function, it could represent a major advance in the treatment of muscle-invasive bladder cancer. The trial’s success could offer a less invasive and more patient-friendly alternative to traditional surgery.
The FDA recently approved an Agilent CDx assay for use with Bristol Myers Squibb immunotherapies, as reported by 360dx, demonstrating ongoing advancements in diagnostic tools used alongside immunotherapy treatments.
Researchers will continue to monitor patients in the INDIBLADE trial to assess the long-term durability of the response and identify factors that predict which patients are most likely to benefit from this treatment approach. The next steps involve analyzing the complete data set from the Phase 2 trial and potentially moving towards a larger Phase 3 trial to confirm these findings and establish the new treatment as a standard of care.
This research offers a hopeful avenue for patients facing a challenging diagnosis. If you or someone you know has been diagnosed with bladder cancer, it’s key to discuss all treatment options with a qualified medical oncologist.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a healthcare professional for diagnosis and treatment of any medical condition.
Share your thoughts and experiences in the comments below.
